Finoriq research workspace
Boundless Bio, Inc. (BOLD) Institutional Holdings & 13F Ownership
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating. Review BOLD institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
- Company
- Boundless Bio, Inc. (BOLD)
- Ticker
- BOLD
- Market Cap
- $55.5M
- Latest Price
- $2.47
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.